Scienmag

OCTOBER 23, 2020

Oncotarget recently published a novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo which reported that here, the authors describe four novel formats for the L19-IL2 fusion Credit: Correspondence to – Dario Neri – dario.neri@pharma.ethz.ch

Recombinant Antibody 53

Recombinant Antibody Protein Antibody In-Vivo 53

Scienmag

NOVEMBER 4, 2020

Credit: Rayne Zaayman-Gallant/EMBL The ability of SARS-CoV-2 to infect cells depends on interactions between the viral spike protein and the human cell surface protein ACE2. To enable the virus to hook onto the cell surface, the spike protein binds ACE2 using three finger-like protrusions, called the receptor binding domains (RBDs).

Scientist 65

Scientist Antibody Protein Medicine 65

Pharmaceutical Technology

DECEMBER 7, 2022

Researchers are also investigating blood-based biomarkers to bolster efforts to find Alzheimer’s drugs that go beyond targeting the amyloid protein, so new targets can be tackled, potentially widening the pool of patients who may respond to a therapy. Lecanemab is an amyloid antibody that targets oligomers and protofibrils of amyloid.

Development 246

Development Drugs Clinical Trials Clinical Trials 246

XTalks

JANUARY 6, 2021

Researchers at the National Institutes of Health (NIH) in the US have isolated small antibodies called “nanobodies” from a llama named Cormac that can block the SARS-CoV-2 coronavirus. Nanobodies are about a quarter of the size, and approximately one tenth of the weight, of a typical human antibody.

Antibody 105

Antibody Protein Bacteria In-Vitro 105

Scienmag

MAY 6, 2021

Inserting active-agent proteins into cancer cells using antibodies The ability of antibodies to recognize specific cancer cells is used in oncology to specifically target those cells with small active agents.

Protein 75

Protein Antibody Scientist Drugs 75

Pharmaceutical Technology

NOVEMBER 29, 2022

For this approach, the team leveraged an oncolytic herpes simplex virus for releasing chemokines, which are signalling proteins that aid in attracting immune cells to tumours. Using chemokines, the scientists made the GBM tumours “hot”, making the chemokines aid in the immune cell migration to the tumour microenvironment.

Development 130

Development Research Antibody Engineer 130

Pharmaceutical Technology

APRIL 28, 2023

Its scope includes Syngene providing integrated drug discovery and development solutions in discovery chemistry and biology, peptide chemistry, antibody and protein reagents, pharmacokinetics and drug metabolism, and pharmaceutical development. until 2026. Syngene’s collaboration with Zoetis started in 2011.

Manufacturing 130

Manufacturing Antibody Clinical Supply Protein 130

Pharmaceutical Technology

JULY 5, 2022

Researchers at the UNC School of Medicine have discovered that hepatitis A virus (HAV) replication needs particular interactions between the human protein ZCCHC14 and TENT4 poly(A) polymerases, a group of enzymes. In addition, the scientists later found that the HAV needs TENT4A/B for its replication.

Protein 130

Protein RNA Genome Genomics 130

Medical Xpress

DECEMBER 1, 2022

In 2021, a group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate containing an adjuvant, a substance that enhances immune responses, elicited durable neutralizing antibody responses to SARS-CoV-2 (..)

Vaccination 75

Vaccination Vaccine Immune Response Containment 75

Pharmaceutical Technology

MAY 19, 2023

The contentious battle is centred around two monoclonal antibodies that inhibit the protein PCSK9, which in turn lowers low-density lipoprotein (LDL) cholesterol levels. According to the company, such an approach is dangerous since companies could claim a whole genus of antibodies without discovering them.

Drugs 147

Drugs Antibody Protein Scientist 147

pharmaphorum

JANUARY 20, 2021

Laboratory studies have confirmed that antibodies stimulated by Pfizer and BioNTech’s COVID-19 vaccine can neutralise the new, more transmissible variant of SARS-CoV-2 identified in the UK. VOC 202012/01 has an unusually high number of genetic changes however, with 10 mutations affecting the spike protein. lineage or VOC 202012/01.

Vaccination 98

Vaccination Vaccine Antibody Protein 98

The Pharma Data

OCTOBER 27, 2021

A study conducted by a consortium of Brazilian researchers has demonstrated that a hyperimmune serum consisting of purified antibody fragments produced in horses may be an efficient approach to combat COVID-19. The neutralizing activity of the sera developed by the scientists has been proved to be high against the P.1 1 (Gamma) and P.2

Antibody 52

Antibody Protein Scientist Clinical Trials 52

Pharmaceutical Technology

APRIL 26, 2023

This investment will be used to further the development of the Singapore-based pharmaceutical company’s solid tumour-focused monoclonal antibodies. Albatroz Therapeutics is developing first-in-class antibody therapeutics for solid tumours and arthritic disorders. Outram Bio and SEEDS Capital led the successful funding round.

Development 256

Development Drugs Marketing Protein 256

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants. bioRxiv [Preprint]. 2021 Apr 8:2021.04.08.438884. Source link: [link].

Protein 52

Protein Vaccination Vaccine Antibody 52

The Pharma Data

SEPTEMBER 30, 2021

Scientists from the German Cancer research facility (DKFZ) and therefore the Medical Faculty Mannheim, Heidelberg University, have now identified a replacement protein produced by blood vessels that permits tumor cells to metastatically colonize organs.

Protein 52

Protein Scientist Antibody Research 52

XTalks

DECEMBER 12, 2023

Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin. Patients have better quality of life thanks to many Grifols plasma-derived medicines that replace missing or deficient plasma proteins.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

The Pharma Data

NOVEMBER 2, 2020

2, 2020 — An experimental antibody drug that targets one of the body’s key metabolism regulators may help obese people lose weight — at least briefly. It would take much more research to prove the antibody is safe and effective, Ryan said. Scientists have tried giving modified versions of FGF21 to benefit metabolism.

Antibody 52

Antibody Drugs Hormones Insulin 52

pharmaphorum

MARCH 28, 2022

Israel-based AION Labs and German independent research institute BioMed X announced its third global call for applications to form a new start-up company focused on using AI to design and optimise antibodies for targeted therapies. . The partners want to focus on riskier, more complex structures of proteins to try to decipher them.

Pharma Companies 98

Pharma Companies Antibody Protein Development 98

pharmaphorum

MAY 19, 2022

Moderna’s vaccines deliver HIV-specific antigens discovered by researchers at IAVI and Scripps Research that have already been tested in a proof-of-concept study carried out last year using an adjuvant protein vaccine approach. HVAD #HVAD2022 pic.twitter.com/KLrVRXtEAv. — Moderna (@moderna_tx) May 18, 2022.

Vaccination 145

Vaccination Vaccine Trials Immune Response 145

XTalks

APRIL 22, 2022

Generally, antibody-based therapeutics are one of the main types of drugs that are assessed using receptor occupancy assays as they bind to specific cell surface receptors through which they impact downstream intracellular signalling pathways. The antibodies are conjugated to fluorochromes for them to be detected.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

Pharmaceutical Technology

AUGUST 24, 2022

More than three decades ago, scientists at the National Cancer Institute began exploring ways to fight cancer using the patient’s immune system. The global immunotherapy market, which includes CAR T-cell therapy, adoptive cell therapies, checkpoint inhibitors, monoclonal antibodies, and other immunotherapies, is expected to grow by 10.1%

Clinical Trials 130

Clinical Trials Clinical Trials Trials Development 130

The Pharma Data

AUGUST 18, 2020

REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection. About REGN-COV2 REGN-COV2 was designed specifically by Regeneron scientists to block infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron will distribute REGN-COV2 in the U.S.

Antibody 52

Antibody Clinical Trials Clinical Trials Manufacturing 52

pharmaphorum

JUNE 30, 2021

AdCOVID was able to stimulate antibodies that bound the SARS-CoV-2 spike protein and were able to neutralise the virus, but not in sufficient quantities and in too few patients.

Vaccination 98

Vaccination Vaccine Trials Immune Response 98

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

pharmaphorum

MARCH 1, 2021

COVID-19 antigen tests diagnose active infection by detecting SARS-CoV-2 viral proteins in samples, as opposed to PCR tests which detect viral RNA and require lab processing, but can miss infections with low virus levels.

In-Vitro 98

In-Vitro RNA Protein Antibody 98

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccination 52

Vaccination Vaccine Protein Immune Response 52

The Pharma Data

SEPTEMBER 15, 2020

” BigHat Biosciences: BigHat Biosciences is an early-stage Bay Area startup reimagining antibody discovery and engineering to create better antibodies faster and undertake novel designs far beyond what’s possible today. About MBC BioLabs MBC BioLabs is dedicated to helping life-science startups succeed.

Life Science 52

Life Science Protein Antibody Scientist 52

pharmaphorum

DECEMBER 1, 2022

Learn how to implement 3D Cell Culture techniques for antibody and cell and gene therapy discovery process. Etienne De Braekeleer, Senior Research Scientist, AstraZeneca. Academia – Cell Technology, Stem Cell Sciences, Biochemistry, Protein Technology and Tissue Engineering.

In-Vitro 52

In-Vitro Scientist Engineer Gene Therapy 52

The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. The full manuscript of the preclinical data is available on the pre-print server bioRxiv. “In

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

pharmaphorum

SEPTEMBER 28, 2022

There’s a new player on the antibody-drug conjugate (ADC) scene. Damour’s co-founders are ADC scientist Paul Jackson – formerly of King’s College London – who will serve as vice president of R&D, as well as Jackson’s former boss at KCL, Prof David Thurston, who will act as an advisor to the new company.

Antibody 52

Antibody Drugs Licensing Licensing 52

Delveinsight

AUGUST 27, 2020

As observed in 45 younger adults, the middle dose of the vaccine triggered the production of neutralizing antibodies against SARS-CoV-2, the virus, which causes COVID-19 , in 10 patients aged 56 to 70 and 10 patients over 71. The BET inhibitor worked by increasing beta-3 tubulin (TUBB3), a protein found in brain metastases.

Vaccination 53

Vaccination Vaccine Research Trials 53

The Pharma Data

OCTOBER 28, 2020

NASDAQ: REGN) today announced positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints. Regeneron Pharmaceuticals, Inc. Yancopoulos , M.D., President and Chief Scientific Officer of Regeneron.

Antibody 40

Antibody Trials Production Clinical Trials 40

Delveinsight

AUGUST 6, 2020

ZyCoV-D is designed to introduce DNA that encodes for a viral protein into human cells. By ordering human cells to make the protein, ZyCoV-D could cause an immune response against the coronavirus. In a new study that is published in Science, the team displayed that one soluble receptor protein, sACE2.v2.4,

Allergies 53

Allergies Vaccination Vaccine Gene Therapy 53

The Pharma Data

DECEMBER 5, 2020

(NASDAQ: REGN) today announced updated data for REGN5458, a BCMAxCD3 bispecific antibody, from the Phase 1 portion of a Phase 1/2 trial in patients with relapsed or refractory (R/R) multiple myeloma. BCMA (B-cell maturation antigen) is a protein that is typically over-expressed on multiple myeloma cells.

Antibody 40

Antibody Production Trials Medicine 40

Delveinsight

AUGUST 13, 2020

Roche has transferred its anti-CSF1R monoclonal antibody emactuzumab to Celleron Therapeutics. Protein implication in Alzheimer’s could enhance cancer immunotherapy. Now, scientists have elucidated a potential use for the protein in cancer treatment. Roche offloads clinical-phase cancer drug to Celleron.

Trials 52

Trials Research Drugs Protein 52

The Pharma Data

NOVEMBER 10, 2020

Elektrofi is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs. Headquartered in Boston, the company’s founding team of MIT engineers and scientists are shaping the future of biologics delivery.

Development 52

Development Engineer Manufacturing Life Science 52

The Pharma Data

APRIL 7, 2023

One of the greatest challenges in modern drug design is to find compounds that satisfy somewhat contradictory requirements – they need to be small enough to permeate human cell membranes, while being large enough to target various protein surfaces and protein–protein interactions.

Drugs 40

Drugs Protein Bioavailability Research 40